Hattori Takashi, Mine Takashi, Komatsu Nobukazu, Yamada Akira, Itoh Kyogo, Shiozaki Hitoshi, Okuno Kiyotaka
Department of Surgery, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan.
Cancer Immunol Immunother. 2009 Nov;58(11):1843-52. doi: 10.1007/s00262-009-0695-6. Epub 2009 Apr 26.
To investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of UFT and UZEL for metastatic colorectal carcinoma (mCRC), fourteen patients were enrolled in the present study. Peptides were determined based on the presence of peptide-specific cytotoxic T lymphocyte precursors and IgG in each patient. A maximum of four peptides were subcutaneously administered weekly with UFT (300 mg/m2 day(-1)) and UZEL (75 mg/day) for 4 weeks, followed by 1 week of rest. This therapy was well-tolerated although there was a grade-3 skin reaction at the vaccination site in one patient. An increase in peptide-specific interferon-gamma production or peptide-specific IgG after the tenth vaccination was observed in nine of ten or eight of ten patients tested, respectively. IgG responses were well correlated with overall survival (P = 0.0215). The safety and immunological responsiveness of the present therapy suggest that this combination would be of clinical benefit for mCRC patients, and further trials are merited.
为研究个性化肽疫苗联合口服优福定（UFT）和乌苯美司（UZEL）治疗转移性结直肠癌（mCRC）的安全性和免疫反应，本研究纳入了14例患者。根据每位患者体内肽特异性细胞毒性T淋巴细胞前体和IgG的情况确定肽段。最多四种肽段每周皮下注射，同时给予优福定（300 mg/m2 每日1次）和乌苯美司（75 mg/日），持续4周，随后休息1周。尽管有1例患者在疫苗接种部位出现3级皮肤反应，但该治疗耐受性良好。在接受检测的10例患者中的9例或10例患者中的8例中，分别观察到第10次接种后肽特异性干扰素-γ产生增加或肽特异性IgG增加。IgG反应与总生存期密切相关（P = 0.0215）。本治疗的安全性和免疫反应性表明，这种联合治疗对mCRC患者具有临床益处，值得进一步试验。
